Microneutralization assay for detection of antibodies against dengue virus serotype 2
Descripción del Articulo
Objective: Adapt the microneutralization test (MNT) to detect neutralizing antibodies against dengue serotype 2 virus (DENV-2) in the Vero-76 cell line. Materials and methods. Different cellular concentrations (0.6 x 105 cell / mL, 0.9 x 105 cell / mL, 1.2 x 105 cell / mL) and percentages...
Autores: | , , , , , , , , |
---|---|
Formato: | artículo |
Fecha de Publicación: | 2023 |
Institución: | Colegio Médico del Perú |
Repositorio: | Acta Médica Peruana |
Lenguaje: | español |
OAI Identifier: | oai:ojs.pkp.sfu.ca:article/2538 |
Enlace del recurso: | https://amp.cmp.org.pe/index.php/AMP/article/view/2538 |
Nivel de acceso: | acceso abierto |
Materia: | Dengue Serotype Neutralization Optimization Immunoglobulin |
id |
REVCMP_f109c4699dbe694b557b01efea2c6bc8 |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/2538 |
network_acronym_str |
REVCMP |
network_name_str |
Acta Médica Peruana |
repository_id_str |
. |
spelling |
Microneutralization assay for detection of antibodies against dengue virus serotype 2Prueba de microneutralización para detección la de anticuerpos contra el virus dengue serotipo 2Sevilla Drozdek, Lucas AugustoMayta Huatuco, EgmaMamani Zapana, EnriqueReyes Puma, NoraVásquez Cajachahua, KarlaQuispe Bravo, BernardoHermosilla Jara, JoeQuintana Bedoya, AdriánSulca Herencia, JuanDengueSerotypeNeutralizationOptimizationImmunoglobulinObjective: Adapt the microneutralization test (MNT) to detect neutralizing antibodies against dengue serotype 2 virus (DENV-2) in the Vero-76 cell line. Materials and methods. Different cellular concentrations (0.6 x 105 cell / mL, 0.9 x 105 cell / mL, 1.2 x 105 cell / mL) and percentages of fetal bovine serum (FBS) at 2%, 3% and 4%, passages number of virus stock and incubation days were evaluated. The viral seed was confirmed by RT-qPCR. DENV-2 was propagated by carrying out 5 successive passages in the Vero-76 cell line, then the virus was titrated in microplates and 2 methods were evaluated: complete monolayer and cell suspension, and the optimal coloring day was determined. Obtained the results, it was evaluated by the MNT for DENV-2: 5 sera negative to DENV-2 and YFV, 5 sera negative to DENV-2 and seropositive to YFV and 5 seropositive sera to DENV-2 confirmed by plaque reduction neutralization test. The samples were evaluated in triplicate and virus control and cell control were used. Results: The optimal method for MNT uses cells in suspension (0.9 x 105 cell / mL), 2% SBF and viral seed passage 5. The minimum dilution capable of differentiating a DENV-2 seropositive serum from a DENV-2 seronegative sera was 1:40, and the incubation time of the MNT for DENV-2 was 10 days. Conclusion: MNT allows the detection of IgG antibodies against DENV-2, provides reliable results and a greater number of samples can be analyzed with material savings.Objetivo: Estandarizar la prueba de microneutralización (MNT) para detección de anticuerpos neutralizantes contra el virus dengue serotipo 2 (DENV-2) en la línea celular Vero-76. Materiales y métodos: Se evaluaron diferentes concentraciones celulares (0,6 x105 cel/mL, 0,9 x105 cel/mL, 1,2 x105 cel/mL), porcentajes de 2%, 3% y 4% de suero bovino fetal (SBF), número de pasajes del stock de virus y los días de incubación. La semilla viral se confirmó por RT-qPCR. El DENV-2 se propagó realizando 5 pasajes en células Vero-76, seguidamente se tituló el virus en placas de 96 pozos y se evaluaron 2 métodos de infección celular: monocapa y células en suspensión, además se determinó el día óptimo de coloración de las células. Obtenidos los resultados, se procesaron mediante MNT para DENV-2 las siguientes muestras: 5 sueros negativos a DENV-2 y YFV, 5 sueros negativos a DENV-2 y positivos a YFV y 5 sueros positivos a DENV-2 seleccionados mediante la prueba de neutralización por reducción de placas (PRNT) Resultados: El método óptimo para MNT utilizó células en suspensión (0,9 x 105 cel/mL), 2% de SBF y semilla viral pasaje 5. La mínima dilución capaz de diferenciar una muestra positiva a DENV-2 fue 1:40 y el tiempo de incubación para la MNT para DENV-2 fue de 10 días. Conclusión: La MNT permite detectar anticuerpos neutralizantes IgG contra DENV-2, brinda resultados fiables y se puede analizar un mayor número de muestras con ahorro de materiales.Colegio Médico del Perú2023-08-02info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://amp.cmp.org.pe/index.php/AMP/article/view/253810.35663/amp.2023.402.2538ACTA MEDICA PERUANA; Vol 40 No 2 (2023): April - JuneACTA MEDICA PERUANA; Vol. 40 Núm. 2 (2023): Abril - Junio1728-59171018-8800reponame:Acta Médica Peruanainstname:Colegio Médico del Perúinstacron:CMPspahttps://amp.cmp.org.pe/index.php/AMP/article/view/2538/1561Copyright (c) 2023 ACTA MEDICA PERUANAinfo:eu-repo/semantics/openAccessoai:ojs.pkp.sfu.ca:article/25382024-03-21T00:09:26Z |
dc.title.none.fl_str_mv |
Microneutralization assay for detection of antibodies against dengue virus serotype 2 Prueba de microneutralización para detección la de anticuerpos contra el virus dengue serotipo 2 |
title |
Microneutralization assay for detection of antibodies against dengue virus serotype 2 |
spellingShingle |
Microneutralization assay for detection of antibodies against dengue virus serotype 2 Sevilla Drozdek, Lucas Augusto Dengue Serotype Neutralization Optimization Immunoglobulin |
title_short |
Microneutralization assay for detection of antibodies against dengue virus serotype 2 |
title_full |
Microneutralization assay for detection of antibodies against dengue virus serotype 2 |
title_fullStr |
Microneutralization assay for detection of antibodies against dengue virus serotype 2 |
title_full_unstemmed |
Microneutralization assay for detection of antibodies against dengue virus serotype 2 |
title_sort |
Microneutralization assay for detection of antibodies against dengue virus serotype 2 |
dc.creator.none.fl_str_mv |
Sevilla Drozdek, Lucas Augusto Mayta Huatuco, Egma Mamani Zapana, Enrique Reyes Puma, Nora Vásquez Cajachahua, Karla Quispe Bravo, Bernardo Hermosilla Jara, Joe Quintana Bedoya, Adrián Sulca Herencia, Juan |
author |
Sevilla Drozdek, Lucas Augusto |
author_facet |
Sevilla Drozdek, Lucas Augusto Mayta Huatuco, Egma Mamani Zapana, Enrique Reyes Puma, Nora Vásquez Cajachahua, Karla Quispe Bravo, Bernardo Hermosilla Jara, Joe Quintana Bedoya, Adrián Sulca Herencia, Juan |
author_role |
author |
author2 |
Mayta Huatuco, Egma Mamani Zapana, Enrique Reyes Puma, Nora Vásquez Cajachahua, Karla Quispe Bravo, Bernardo Hermosilla Jara, Joe Quintana Bedoya, Adrián Sulca Herencia, Juan |
author2_role |
author author author author author author author author |
dc.subject.none.fl_str_mv |
Dengue Serotype Neutralization Optimization Immunoglobulin |
topic |
Dengue Serotype Neutralization Optimization Immunoglobulin |
description |
Objective: Adapt the microneutralization test (MNT) to detect neutralizing antibodies against dengue serotype 2 virus (DENV-2) in the Vero-76 cell line. Materials and methods. Different cellular concentrations (0.6 x 105 cell / mL, 0.9 x 105 cell / mL, 1.2 x 105 cell / mL) and percentages of fetal bovine serum (FBS) at 2%, 3% and 4%, passages number of virus stock and incubation days were evaluated. The viral seed was confirmed by RT-qPCR. DENV-2 was propagated by carrying out 5 successive passages in the Vero-76 cell line, then the virus was titrated in microplates and 2 methods were evaluated: complete monolayer and cell suspension, and the optimal coloring day was determined. Obtained the results, it was evaluated by the MNT for DENV-2: 5 sera negative to DENV-2 and YFV, 5 sera negative to DENV-2 and seropositive to YFV and 5 seropositive sera to DENV-2 confirmed by plaque reduction neutralization test. The samples were evaluated in triplicate and virus control and cell control were used. Results: The optimal method for MNT uses cells in suspension (0.9 x 105 cell / mL), 2% SBF and viral seed passage 5. The minimum dilution capable of differentiating a DENV-2 seropositive serum from a DENV-2 seronegative sera was 1:40, and the incubation time of the MNT for DENV-2 was 10 days. Conclusion: MNT allows the detection of IgG antibodies against DENV-2, provides reliable results and a greater number of samples can be analyzed with material savings. |
publishDate |
2023 |
dc.date.none.fl_str_mv |
2023-08-02 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
https://amp.cmp.org.pe/index.php/AMP/article/view/2538 10.35663/amp.2023.402.2538 |
url |
https://amp.cmp.org.pe/index.php/AMP/article/view/2538 |
identifier_str_mv |
10.35663/amp.2023.402.2538 |
dc.language.none.fl_str_mv |
spa |
language |
spa |
dc.relation.none.fl_str_mv |
https://amp.cmp.org.pe/index.php/AMP/article/view/2538/1561 |
dc.rights.none.fl_str_mv |
Copyright (c) 2023 ACTA MEDICA PERUANA info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2023 ACTA MEDICA PERUANA |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Colegio Médico del Perú |
publisher.none.fl_str_mv |
Colegio Médico del Perú |
dc.source.none.fl_str_mv |
ACTA MEDICA PERUANA; Vol 40 No 2 (2023): April - June ACTA MEDICA PERUANA; Vol. 40 Núm. 2 (2023): Abril - Junio 1728-5917 1018-8800 reponame:Acta Médica Peruana instname:Colegio Médico del Perú instacron:CMP |
instname_str |
Colegio Médico del Perú |
instacron_str |
CMP |
institution |
CMP |
reponame_str |
Acta Médica Peruana |
collection |
Acta Médica Peruana |
repository.name.fl_str_mv |
|
repository.mail.fl_str_mv |
|
_version_ |
1816075112248508416 |
score |
13.95948 |
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).